Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy ACOG?
Source: Newsfilter
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.870
Low
18.00
Averages
18.00
High
18.00
Current: 5.870
Low
18.00
Averages
18.00
High
18.00
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
See More
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
Alpha Cognition Launches BEACON Study for ZUNVEYL
- Study Launch: Alpha Cognition has announced the enrollment of the first patient in the BEACON study, aimed at assessing the effectiveness of ZUNVEYL® in long-term care settings, marking a significant milestone in the treatment of Alzheimer's disease.
- Study Scale and Objectives: The study is expected to enroll approximately 200 patients, focusing on collecting data on ZUNVEYL's impact on cognition and neuropsychiatric symptoms, thereby providing practice-relevant evidence to support the company's commercialization efforts in a high-need area.
- Data Generation and Application: The BEACON study will generate data through routine clinical practice to complement earlier trial findings, and if results are positive, it will further strengthen the clinical foundation for ZUNVEYL and support its commercial launch.
- Future Outlook: Alpha Cognition anticipates reporting topline results in Q4 2026, which, if successful, will provide robust support for the company's competitive position in the Alzheimer's treatment market.
See More
Alpha Cognition Secures New Patent Protection
- Patent Protection Extended: The U.S. Patent and Trademark Office has granted Alpha Cognition a patent covering oral dosing regimens of benzgalantamine for mild to moderate Alzheimer's disease, expected to provide U.S. patent protection until July 2045, thereby enhancing the company's competitive position in this sector.
- IP Strategy Strengthened: The issuance of the new patent significantly bolsters the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens, which not only enhances its commercial value but also lays the groundwork for long-term differentiation in the U.S. market.
- Innovative Drug Development: ZUNVEYL, as a new generation acetylcholinesterase inhibitor, is expected to have minimal gastrointestinal side effects, with its active metabolite uniquely binding to neuronal nicotinic receptors, thereby improving cognitive function and further driving innovation in Alzheimer's treatment.
- Market Outlook: Alpha Cognition is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia, showcasing the company's extensive portfolio in neurodegenerative disease treatments and indicating potential growth opportunities in the future.
See More
Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025
- Upcoming Virtual Event: Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, where CEO Michael McFadden will discuss the company's commercialization efforts and research initiatives in neurodegenerative disease therapies.
- Product Overview: The company’s ZUNVEYL® is an FDA-approved next-generation treatment for Alzheimer’s disease, expected to significantly enhance cognitive function in patients while minimizing gastrointestinal side effects.
- Market Potential: ZUNVEYL®'s active metabolite uniquely binds to neuronal α7 receptors, differentiating it from existing treatments and positioning it to meet the growing demand in the Alzheimer’s treatment market.
- Future Outlook: The company plans to develop ZUNVEYL® in combination with memantine for moderate to severe Alzheimer’s dementia, indicating strong long-term growth potential in addressing significant unmet medical needs.
See More
Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025
- Commercialization Efforts: Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, hosted by Titan Partners, focusing on its commercialization efforts aimed at accelerating the market adoption of its drug ZUNVEYL for neurodegenerative diseases.
- CEO Participation: CEO Michael McFadden will discuss the company's research initiatives and business strategies during the chat, emphasizing the innovation and market potential in the Alzheimer's treatment sector.
- New Drug ZUNVEYL: ZUNVEYL is an FDA-approved next-generation drug designed for Alzheimer's patients, expected to have minimal gastrointestinal side effects, addressing the current lack of effective treatment options in the market.
- Market Outlook: The company anticipates that ZUNVEYL will play a significant role in the long-term care market, although it faces risks related to capital raising and market adoption, its unique mechanism of action may drive future growth.
See More
Alpha Cognition to Present ZUNVEYL Clinical Data at Upcoming Conferences
- Clinical Data Presentation: Alpha Cognition will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists from April 16-20, 2026, and at the Neuroscience Education Institute Spring Congress from May 1-3, 2026, further characterizing its clinical profile in Alzheimer's disease patients.
- Poster Presentation Details: The company will showcase multiple posters, including studies on the clinical benefits of galantamine and benzgalantamine in Alzheimer's disease, which are expected to attract significant attention from the scientific community and potentially enhance ZUNVEYL's market recognition.
- Commitment to Innovation: Chief Scientific Officer Dennis Kay stated that these findings not only deepen the understanding of ZUNVEYL's potential but also reflect the company's commitment to improving outcomes for patients and caregivers through innovative approaches, which may enhance the company's reputation in the biopharmaceutical sector.
- Market Potential: As an FDA-approved next-generation acetylcholinesterase inhibitor, ZUNVEYL is expected to provide new treatment options for Alzheimer's disease patients, addressing the current lack of effective therapies in the market, thus holding significant commercial value.
See More
Solas Capital Initiates New Position in Kyndryl
- New Position Disclosure: On February 17, 2026, Solas Capital Management disclosed a new position in Kyndryl by acquiring 407,634 shares valued at $10.83 million, reflecting both confidence in the company and concerns over market volatility.
- Asset Allocation Change: This acquisition represents 6.14% of Solas Capital's reportable assets under management, indicating Kyndryl's significance in the investment portfolio, despite its stock price plummeting by 67.5% over the past year.
- Financial Performance Overview: Kyndryl's latest financial metrics reveal a trailing twelve-month revenue of $15.12 billion and a net income of $249 million, with a market capitalization of $3.06 billion, highlighting ongoing challenges in the IT infrastructure services sector, particularly in its partnership with IBM.
- Uncertain Market Outlook: While Solas Capital's investment in Kyndryl has garnered attention, the company's delay in filing its 10-Q and the resignation of key executives have led investors to adopt a cautious stance regarding its future sales cycles and market performance, potentially impacting further stock price volatility.
See More
Alpha Cognition Launches BEACON Study for ZUNVEYL
- Study Launch: Alpha Cognition has announced the enrollment of the first patient in the BEACON study, aimed at assessing the effectiveness of ZUNVEYL® in long-term care settings, marking a significant milestone in the treatment of Alzheimer's disease.
- Study Scale and Objectives: The study is expected to enroll approximately 200 patients, focusing on collecting data on ZUNVEYL's impact on cognition and neuropsychiatric symptoms, thereby providing practice-relevant evidence to support the company's commercialization efforts in a high-need area.
- Data Generation and Application: The BEACON study will generate data through routine clinical practice to complement earlier trial findings, and if results are positive, it will further strengthen the clinical foundation for ZUNVEYL and support its commercial launch.
- Future Outlook: Alpha Cognition anticipates reporting topline results in Q4 2026, which, if successful, will provide robust support for the company's competitive position in the Alzheimer's treatment market.
See More
Alpha Cognition Secures New Patent Protection
- Patent Protection Extended: The U.S. Patent and Trademark Office has granted Alpha Cognition a patent covering oral dosing regimens of benzgalantamine for mild to moderate Alzheimer's disease, expected to provide U.S. patent protection until July 2045, thereby enhancing the company's competitive position in this sector.
- IP Strategy Strengthened: The issuance of the new patent significantly bolsters the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens, which not only enhances its commercial value but also lays the groundwork for long-term differentiation in the U.S. market.
- Innovative Drug Development: ZUNVEYL, as a new generation acetylcholinesterase inhibitor, is expected to have minimal gastrointestinal side effects, with its active metabolite uniquely binding to neuronal nicotinic receptors, thereby improving cognitive function and further driving innovation in Alzheimer's treatment.
- Market Outlook: Alpha Cognition is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia, showcasing the company's extensive portfolio in neurodegenerative disease treatments and indicating potential growth opportunities in the future.
See More
Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025
- Upcoming Virtual Event: Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, where CEO Michael McFadden will discuss the company's commercialization efforts and research initiatives in neurodegenerative disease therapies.
- Product Overview: The company’s ZUNVEYL® is an FDA-approved next-generation treatment for Alzheimer’s disease, expected to significantly enhance cognitive function in patients while minimizing gastrointestinal side effects.
- Market Potential: ZUNVEYL®'s active metabolite uniquely binds to neuronal α7 receptors, differentiating it from existing treatments and positioning it to meet the growing demand in the Alzheimer’s treatment market.
- Future Outlook: The company plans to develop ZUNVEYL® in combination with memantine for moderate to severe Alzheimer’s dementia, indicating strong long-term growth potential in addressing significant unmet medical needs.
See More
Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025
- Commercialization Efforts: Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, hosted by Titan Partners, focusing on its commercialization efforts aimed at accelerating the market adoption of its drug ZUNVEYL for neurodegenerative diseases.
- CEO Participation: CEO Michael McFadden will discuss the company's research initiatives and business strategies during the chat, emphasizing the innovation and market potential in the Alzheimer's treatment sector.
- New Drug ZUNVEYL: ZUNVEYL is an FDA-approved next-generation drug designed for Alzheimer's patients, expected to have minimal gastrointestinal side effects, addressing the current lack of effective treatment options in the market.
- Market Outlook: The company anticipates that ZUNVEYL will play a significant role in the long-term care market, although it faces risks related to capital raising and market adoption, its unique mechanism of action may drive future growth.
See More
